Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:15 2024-06-20 EDT			After market 12:46:51
2.065 ^EUR	-3.50%		2.043	-1.07%

05-23	Transcript : Vivoryon Therapeutics N.V., Q1 2024 Earnings Call, May 23, 2024
04-24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024

Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

May 23, 2024 at 02:35 am

Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date23 may 2024 - 07:07

Statutory nameVivoryon Therapeutics N.V.

TitleVivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

Previous result

Next result

Related downloads

202405230000000001_Vivoryon_Q1 2024 .pdf(opens in a new window)

Date last update: 23 May 2024

Attachments

Original Link
Permalink

Disclaimer

Vivoryon Therapeutics NV published this content on 23 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2024 06:34:03 UTC.

Latest news about Vivoryon Therapeutics N.V.

Transcript : Vivoryon Therapeutics N.V., Q1 2024 Earnings Call, May 23, 2024	05-23
Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024	04-24
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	03-15	CI
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	03-04	CI
Transcript : Vivoryon Therapeutics N.V., Q3 2023 Earnings Call, Dec 06, 2023	12-06
Vivoryon Therapeutics N.V. Announces Executive Changes	12-06	CI
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	CI
Transcript : Vivoryon Therapeutics N.V. - Special Call	23-10-17
Vivoryon Therapeutics N.V. Announces Board Appointments	23-09-15	CI
Transcript : Vivoryon Therapeutics N.V., H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Certain Shares of Vivoryon Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Vivoryon Therapeutics Promotes Chief Medical Officer to CEO	23-08-07	MT
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimerâ€™s Disease	23-07-16	CI
Vivoryon Therapeutics N.V. Approves Board Appointments	23-06-21	CI
Vivoryon Therapeutics CEO to Step Down in FY24	23-06-16	MT
Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO	23-06-15	CI
Vivoryon Rises 7% on EUR25 Million Capital Raise	23-05-26	MT
Vivoryon Therapeutics N.V. Announces Resignation of Dinnies Johannes Von Der Osten, PhD, and Jörg Neermann, PhD from the Board of Directors	23-05-01	CI
Transcript : Vivoryon Therapeutics N.V., Q4 2022 Earnings Call, Apr 19, 2023	23-04-19
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Vivoryon Therapeutics N.V. Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease	23-03-28	CI
Transcript : Vivoryon Therapeutics N.V. Presents at Barclays Global Healthcare Conference, Mar-16-2023 08:00 AM	23-03-16

Chart Vivoryon Therapeutics N.V.

Duration

Period

More charts

Company Profile

Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2023, the group has a portfolio of a product in phase II-B clinical development (Varoglutamstat; PQ912).

Sector

Biotechnology & Medical Research

Calendar

2024-06-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.14 EUR

Average target price

41.57 EUR

Spread / Average Target

+1,842.37%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIVORYON THERAPEUTICS N.V.	-74.63%	59.92M
MODERNA, INC.	+34.29%	51.07B
IQVIA HOLDINGS INC.	-8.02%	38.78B
LONZA GROUP AG	+35.88%	38.61B
CELLTRION, INC.	-10.62%	27.32B
ICON PUBLIC LIMITED COMPANY	+11.96%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-18.76%	19.46B
UNITED THERAPEUTICS CORPORATION	+40.47%	13.58B
MEDPACE HOLDINGS, INC.	+28.61%	12.46B
BIO-TECHNE CORPORATION	-3.84%	11.75B

Other Biotechnology & Medical Research